We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

GLP-1 Prescription Renewal: How It Works With Telehealth Programs

A common question a few months into GLP-1 treatment is simple: what happens when the first prescription runs out? Usually, a follow-up check-in with the prescriber, a decision about your dose, and a new prescription if continuing still makes sense for you.

How that works varies a lot between programs. Some build regular check-ins into a monthly fee. Others charge per visit, or leave renewal to you. Knowing what a renewal should involve helps you compare programs before you sign up and spot problems once you start.

How the prescription period works

A prescription is written for a set amount of medication, a set number of refills, and a dose schedule. How long it stays valid depends on what the prescriber writes and on your state’s pharmacy rules. When it runs out or the refills are used up, a refill does not happen automatically. The prescriber has to decide whether to write a new one.

For the FDA-approved products, the dose schedule follows the label. Wegovy injection starts at 0.25 mg once a week and goes up every 4 weeks (0.5 mg, 1 mg, 1.7 mg) to a maintenance dose of 1.7 mg or 2.4 mg, with up to 7.2 mg allowed for some adults.[1] Zepbound starts at 2.5 mg once a week for 4 weeks, then 5 mg, and can go up in 2.5 mg steps after at least 4 weeks on the current dose, to a maintenance dose of 5 mg, 10 mg, or 15 mg.[2] Compounded semaglutide and tirzepatide are not FDA-approved and have no FDA label, so the dosing on a compounded prescription is whatever the prescriber writes. Ask how the dose was chosen.

Because a prescription has an end date, renewal is a point where someone checks whether the plan is working, whether the dose should change, and whether continuing still makes medical sense for you. A program that refills indefinitely without any check-in is worth asking about.

The renewal process: what the provider reviews

At most telehealth programs, a renewal is a short follow-up. Often it is asynchronous: you fill out a check-in form or send a message, and a licensed provider reviews it and responds. Some programs or states require a live visit. Here is what a prescriber usually looks at:

Your progress and side effects. How your weight has changed, which side effects you have had, and whether they are manageable. Also any new health problems, new medications, pregnancy plans, or upcoming surgery. The labels list pulmonary aspiration during anesthesia or deep sedation as a warning, so prescribers ask about planned procedures.[1][2]

Lab results, if any are due. Some prescribers review recent lab work before renewing. Which tests, if any, depends on your health history (see the next section).

How you have been taking it. Missed doses matter. The labels have specific rules for them (see “Requesting a dose change” below), and a gap can mean restarting at a lower dose.

Overall fit. Whether the medication is still appropriate, and whether anything in your health history has changed that would make continuing risky.

Based on that review, the prescriber decides whether to keep the current dose, go up, go down, or stop. If continuing is appropriate, they write a new prescription.

Ongoing lab monitoring schedule

There is no single lab schedule that every GLP-1 program follows. The prescriber decides which tests to order and how often, based on your health history, other conditions such as diabetes or kidney disease, and any side effects you report. For example, the labels advise monitoring kidney function in people with side effects that could cause dehydration, and monitoring people with type 2 diabetes who have a history of diabetic retinopathy.[1][2]

Programs handle labs differently. Some order baseline and follow-up labs through a national lab chain, some accept recent results from your primary care provider, and some include lab costs in a monthly fee while others bill them separately. Questions to ask before you sign up:

  • Which labs are required before starting, and which at renewal?
  • How often are follow-up labs ordered?
  • Are lab costs included, billed separately, or billed to insurance?
  • Who reviews the results, and how will you hear about them?

Our guide to labs required for GLP-1 treatment covers the common tests in more detail.

Requesting a dose change

GLP-1 medications are started at a low dose and increased step by step. The labels say the escalation schedule is there to reduce the risk of gastrointestinal side effects.[1][2]

For Wegovy injection, the label calls for at least 4 weeks at each step, and says a prescriber can delay the next increase by 4 weeks if a dose is not tolerated.[1] For Zepbound, increases come after at least 4 weeks on the current dose, and the label says to consider a lower maintenance dose if a higher one is not tolerated.[2] Going faster than the label allows is not an option the label supports, so a request to skip ahead will usually be turned down.

When you ask for a change, the prescriber usually considers:

  • How long you have been on your current dose
  • How well you are tolerating it
  • How your progress has changed
  • Any recent lab results or health changes

Asking to lower the dose because of side effects is just as reasonable as asking to go up. Either way, the prescriber makes the call. Ask a program how dose-change requests work between scheduled check-ins, and how quickly a new dose can ship.

Missed doses can change the plan. The labels set specific rules:[1][2]

ProductIf you miss a dose
Wegovy injection (weekly)If the next dose is more than 2 days away, take the missed dose as soon as possible. If it is less than 2 days away, skip it and resume on your usual day. If you miss 2 or more doses in a row, the label says to restart dose escalation at a lower dose.
Wegovy tablets (daily)Skip the missed dose and take the next one the following day.
Zepbound (weekly)Take the missed dose as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip it and take the next dose on your usual day.

If you have missed doses, tell the prescriber before your next refill so the dose on the new prescription matches where you are. For compounded products, ask the prescriber and the pharmacy what to do, because there is no FDA label for them. Our missed dose guide has more detail.

Pausing or canceling your program

Cancellation terms vary by program, so read them before you pay. Things to check:

  • Whether billing renews automatically, and how much notice you have to give to cancel
  • Whether there is a minimum commitment, prepayment, or early cancellation fee
  • What happens to a shipment that is already being prepared or has shipped
  • Whether you can pause instead of canceling, and for how long

If you stop: shipments stop and the prescription is not renewed. Weight regain after stopping is common. In the STEP 4 trial of Wegovy (semaglutide 2.4 mg), participants who had lost an average of 10.6% over a 20-week run-in and then switched to placebo regained weight (+6.9% from week 20 to week 68), while those who continued lost a further 7.9%.[3] In SURMOUNT-4, participants who had lost an average of 20.9% on Zepbound (tirzepatide) over 36 weeks and then switched to placebo regained 14.0% over the next 52 weeks, compared with a further 5.5% loss among those who continued.[4] These results describe trial participants taking Wegovy or Zepbound, not compounded versions, and are not a prediction for any individual.

If you restart after a gap: expect a new intake or a shorter re-evaluation. That is a safety step, not a penalty. After a gap, restarting at your old dose may not be appropriate, and the Wegovy label calls for restarting escalation at a lower dose after 2 or more missed doses in a row.[1] The prescriber will also check whether anything in your health history has changed.

Program options to review

Before you choose a program, or before you renew, ask how refills and renewals actually work there. The answers differ a lot:

  • Refill timing. How far ahead of your last dose is the next shipment sent? What happens if a renewal check-in is late, or a pharmacy is out of your dose?
  • Auto-ship. Do refills ship automatically? Can you delay one if you still have medication, or if you need to hold a dose increase?
  • Price changes at higher doses. Many programs and manufacturer self-pay options charge more for higher doses. Ask what you will pay at each dose step, not only the starting dose. Prices vary by program and dose; compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.
  • Renewal visits. Are follow-up check-ins included, or charged per visit? Who does them: a physician, nurse practitioner, or physician assistant?
  • Maintenance. What happens once you reach a maintenance dose? Both labels list maintenance doses (for Wegovy injection, 1.7 mg or 2.4 mg; for Zepbound, 5 mg, 10 mg, or 15 mg).[1][2] Ask how the program decides on a long-term dose and how often it rechecks.
  • Cancellation. Is it easy to cancel online, and are the terms shown before you pay?

State-specific requirements for prescription renewal

Telehealth rules vary by state, including whether a live video visit is needed before a prescription is written or renewed. We have not verified a current state-by-state list, so ask the program directly:

  • Is the prescriber licensed in your state?
  • Does your state, or the program, require a live video visit at renewal?
  • Can the pharmacy legally ship to your state?

If a live visit is required, it is usually a short follow-up on progress, side effects, and whether continuing is appropriate.

If insurance pays: prior authorization renewals

If your plan covers a GLP-1 for weight loss, the first approval usually lasts a set number of months. To keep coverage, your prescriber has to send a renewal request showing that you meet the plan’s continuation criteria. These examples come from insurer documents in effect as of 2026-10-16:

  • Aetna (Wegovy policy): for Wegovy injection in adults, a first approval lasts 8 months and a renewal 12 months. Renewal requires at least 3 months at a stable maintenance dose and a loss of at least 5 percent of baseline body weight, or keeping that initial 5 percent off.[5]
  • UnitedHealthcare (weight loss program effective 10/1/2026): a first approval lasts 5 months for Wegovy and 6 months for Zepbound. Renewals last 12 months and require continued lifestyle changes plus a loss of at least 5 percent of baseline body weight. People on therapy six months or less who have not yet reached a maintenance dose can get a one-time 6-month approval instead.[6]

Your plan’s own criteria are the only ones that count for you, and they can change. Note your starting weight and the date you reached a maintenance dose, and ask your prescriber’s office when the renewal request is due so coverage does not lapse. Our guide to GLP-1 prior authorization covers the paperwork, and the Aetna, UnitedHealthcare, and CVS Caremark pages list each insurer’s criteria in more detail.

Safety information

GLP-1 medications have real risks along with their benefits. Wegovy and Zepbound carry a boxed warning about the risk of thyroid C-cell tumors. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or by people with a known serious allergy to the ingredients. Label warnings include pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastrointestinal reactions, serious allergic reactions, low blood sugar when used with insulin or sulfonylureas, diabetic retinopathy complications in people with type 2 diabetes, and pulmonary aspiration during anesthesia or deep sedation. The most common side effects in the labels include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, fatigue, and hair loss.[1][2] Read the full prescribing information and talk with a licensed provider about your own risks.

Important disclosures

Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality.[7] Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Clinical trial results for Wegovy and Zepbound do not apply to compounded versions.

Results vary. Trial results describe study participants and are not a prediction for any individual.

Citations

[1] Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (sections 2.2-2.4, 5, 6). U.S. Food and Drug Administration. Revised 06/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[2] Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information (sections 2.1-2.3, 5, 6). U.S. Food and Drug Administration. Highlights revised 08/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[3] Rubino D, Abrahamsson N, Davies M, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” JAMA. 2021;325(14):1414-1425. PMID 33755728. https://pubmed.ncbi.nlm.nih.gov/33755728/

[4] Aronne LJ, Sattar N, Horn DB, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. PMID 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/

[5] Aetna. Pharmacy Clinical Policy Bulletin, “Wegovy PA with Limit 4774-C P08-2025 v5.” Dated August 20, 2026. Accessed 2026-10-16. https://www.aetna.com/products/rxnonmedicare/data/2026/Wegovy_PA_with_Limit_4774-C_P08-2025_v5.html

[6] UnitedHealthcare Pharmacy. Clinical Pharmacy Program 2026 P 1114-23, “Prior Authorization/Notification - Weight Loss/Appetite Suppression Medication Coverage.” Effective 10/1/2026. Accessed 2026-10-16. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf

[7] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, renew prescriptions, compound, sell, or ship medication. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Results vary. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Aetna and UnitedHealthcare are named for identification only. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
How often does a GLP-1 prescription need to be renewed?
It depends on what the prescriber writes and on your state's pharmacy rules. A prescription lists how much medication can be dispensed and how many refills are allowed, and it has an end date. When it runs out, the prescriber decides whether to write a new one, usually after a follow-up check-in. Ask any program how long its prescriptions usually run and how renewal check-ins work.
Are lab results reviewed when a prescription is renewed?
Sometimes. There is no single lab schedule for GLP-1 renewals. The prescriber decides which tests to order and how often, based on your health history and how you are doing on the medication. Some programs order labs before starting and at follow-ups; others rely on recent results from your primary care provider. Ask the program what labs it requires, how often, and whether lab costs are included or billed separately.
What if I want to change my dose?
Dose changes are the prescriber's decision. For the FDA-approved products, the labels set the escalation pace. Wegovy injection goes up every 4 weeks, and Zepbound goes up in 2.5 mg steps after at least 4 weeks on the current dose. Both labels say a prescriber can delay or lower the dose if you are not tolerating it. Tell the prescriber about side effects and progress, and ask how dose-change requests are handled between check-ins.
Can I pause or cancel a GLP-1 program?
That depends on the program's terms, so read them before you pay. Some programs bill monthly and renew automatically; some require a multi-month commitment or prepayment. If you stop, ask what happens to a shipment already being prepared. If you restart after a gap, the prescriber may need to restart dose escalation. The Wegovy label, for example, says to restart escalation at a lower dose after 2 or more missed doses in a row.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.